CRIS - Curis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.1100
+0.0500 (+2.43%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.0600
Open2.0300
Bid0.0000 x 3200
Ask2.2500 x 900
Day's Range2.0500 - 2.1500
52 Week Range0.6000 - 2.9000
Volume181,218
Avg. Volume192,487
Market Cap70.058M
Beta (3Y Monthly)2.07
PE Ratio (TTM)N/A
EPS (TTM)-0.9130
Earnings DateOct 30, 2019 - Nov 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • PR Newswire

    Curis Reports Second Quarter 2019 Financial Results

    LEXINGTON, Mass., Aug. 6, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended June 30, 2019. "Today, we are excited to announce initial data from our ongoing Phase 1 study of CA-4948 in patients with non-Hodgkin lymphoma, demonstrating anti-cancer activity for CA-4948 with tumor reduction observed in multiple patients across multiple dose levels," said James Dentzer, President and Chief Executive Officer of Curis. "I am very pleased with the initial data we are seeing in our ongoing Phase 1 trial of CA-4948," said Robert Martell, Head of R&D of Curis.  "As we increase dosing, we have observed continued evidence of pharmacodynamic target inhibition with dose-proportional increases in pharmacokinetic exposure.

  • Curis to Release Second Quarter Financial Results and Hold Conference Call on August 6, 2019
    PR Newswire

    Curis to Release Second Quarter Financial Results and Hold Conference Call on August 6, 2019

    LEXINGTON, Mass., July 30, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter financial results on Tuesday, August 6, 2019, after the close of US markets. Management will host a conference call on the same day at 4:30 p.m. ET. To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 p.m. ET.

  • Could Curis, Inc.'s (NASDAQ:CRIS) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Curis, Inc.'s (NASDAQ:CRIS) Investor Composition Influence The Stock Price?

    If you want to know who really controls Curis, Inc. (NASDAQ:CRIS), then you'll have to look at the makeup of its share...

  • Curis Highlights Publication in Nature Cell Biology Identifying Cancer-Causing Form of IRAK4 in Patients with AML and MDS
    PR Newswire

    Curis Highlights Publication in Nature Cell Biology Identifying Cancer-Causing Form of IRAK4 in Patients with AML and MDS

    LEXINGTON, Mass., June 12, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today highlighted a publication titled "U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies" in Nature Cell Biology.1 The study findings demonstrate that a cancer-causing splicing variant of IRAK4 (IRAK4-L) is dominant in the majority of cases of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Additionally, specific mutations of the U2AF1 splicing factor induce IRAK4-L, which has potential therapeutic targetability by CA-4948, the Company's small molecule inhibitor of IRAK4.

  • Thomson Reuters StreetEvents

    Edited Transcript of CRIS earnings conference call or presentation 14-May-19 8:30pm GMT

    Q1 2019 Curis Inc Earnings Call

  • Associated Press

    Curis: 1Q Earnings Snapshot

    The Lexington, Massachusetts-based company said it had a loss of 30 cents per share. Losses, adjusted to extinguish debt, came to 19 cents per share. The drug developer posted revenue of $2.1 million in ...

  • Curis Reports First Quarter 2019 Financial Results
    PR Newswire

    Curis Reports First Quarter 2019 Financial Results

    LEXINGTON, Mass., May 14, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2019.

  • PR Newswire

    Curis to Release First Quarter Financial Results and Hold Conference Call on May 14, 2019

    LEXINGTON, Mass., May 7, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter financial results on Tuesday, May 14, 2019, after the close of US markets. Management will host a conference call on the same day at 4:30 p.m. ET. To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 p.m. ET.

  • PR Newswire

    Curis Completes Mesothelioma Enrollment in CA-170 Study

    LEXINGTON, Mass., May 6, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Phase 1 study of CA-170 has reached its target enrollment of mesothelioma patients. Today's announcement is a direct result of those efforts," said James Dentzer, President & CEO of Curis. CA-170 is an orally available, dual inhibitor of VISTA and PDL1, which the company believes could provide benefit in tumors with high levels of VISTA expression.

  • Some Curis (NASDAQ:CRIS) Shareholders Have Taken A Painful 83% Share Price Drop
    Simply Wall St.

    Some Curis (NASDAQ:CRIS) Shareholders Have Taken A Painful 83% Share Price Drop

    It is doubtless a positive to see that the Curis, Inc. (NASDAQ:CRIS) share price has gained some 40% in the last three months. But spare a thought for the long term holders, who have held the stock as it bled value over the la...

  • Curis Regains Compliance with Nasdaq Continued Listing Requirements
    PR Newswire

    Curis Regains Compliance with Nasdaq Continued Listing Requirements

    LEXINGTON, Mass., April 10, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it received written confirmation from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying the Company that it has regained compliance with the minimum Market Value of Listed Securities ("MVLS") for continued listing on the Nasdaq Global Market. On December 27, 2018, the Company had received a letter from Nasdaq notifying it that it was not in compliance with the MVLS requirement set forth in Listing Rule 5450(b)(2)(A).

  • Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    PR Newswire

    Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    LEXINGTON, Mass., April 5, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 2, 2019, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase 150,000 shares of Curis common stock to a new employee, with a grant date of April 2, 2019 (the "Q2 2019 Inducement Grant").

  • Thomson Reuters StreetEvents

    Edited Transcript of CRIS earnings conference call or presentation 26-Mar-19 8:30pm GMT

    Q4 2018 Curis Inc Earnings Call

  • Associated Press

    Curis: 4Q Earnings Snapshot

    The Lexington, Massachusetts-based company said it had a loss of 18 cents per share. The drug developer posted revenue of $2.8 million in the period. For the year, the company reported that its loss narrowed ...

  • Curis Reports Fourth Quarter and Year-End 2018 Financial Results
    PR Newswire

    Curis Reports Fourth Quarter and Year-End 2018 Financial Results

    LEXINGTON, Mass., March 26, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year ended December 31, 2018. "2018 was a pivotal year for Curis as we transitioned from a company broadly engaged in discovery research and pipeline expansion into a company singularly focused on clinical execution," said James Dentzer, President and Chief Executive Officer of Curis. "As we move through 2019, we are focused on the development of first-in-class and best-in-class precision medicines that we hope will transform the lives of patients," he concluded.

  • Benzinga

    The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 25) Axsome Therapeutics Inc (NASDAQ: AXSM ) Catalyst Pharmaceuticals ...

  • Benzinga

    What's Driving The Rally In Microcap Biotech Curis?

    Thinly traded Curis, Inc. (NASDAQ: CRIS ) shares weremoving notably higher Monday on roughly 35 times their average volume. What Happened Curis announced Monday ahead of the market open that it reached ...

  • Biotech News: Why Curis Stock Is Soaring Today
    InvestorPlace

    Biotech News: Why Curis Stock Is Soaring Today

    A recent bit of biotech news involving Curis has CRIS stock flying high on Monday.Source: Shutterstock Curis (NASDAQ:CRIS) has announced that it has reached a deal with Oberland Capital Management in connection to Erivedge. This has it offering selling rights for a portion of royalty revenues to the group for $135.70 million.According to Curis, the deal with Oberland Capital Management has it receiving a starting payment of $65.00 million. It is then able to collect additional payments of up to $70.70 million from the company. However, Erivedge must reach certain milestones for CRIS to receive these payments.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe biotech news also includes Curis already making good use of the money from the deal. It notes that it used a portion of the cash from the deal to pay off some of its debts. It is also using the remaining $30 million from the upfront payment to funds its operations."We believe this structure provides Curis with substantial non-dilutive capital today, while retaining significant participation in the future upside potential of Erivedge," James Dentzer, President and CEO of Curis, said in a statement. "The proceeds of this transaction further strengthen our cash position as we fund our three lead therapeutic candidates to reach their near term development catalysts and beyond." * 7 Marijuana Stocks to Play the CBD Trend Erivedge is a drug from Curis that is used to treat patients suffering from Hedgehog signaling due to genetic mutations. The drug does this by targeting a protein called Smoothened.CRIS stock was up 31% as of Monday morning and is up 74% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dual-Class Stocks That Will Outperform * 7 Reasons Why Apple Streaming Won't Move the Needle for Apple Stock * 7 A-Rated Stocks to Buy in the Second Quarter As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Biotech News: Why Curis Stock Is Soaring Today appeared first on InvestorPlace.

  • PR Newswire

    Curis Sells Portion of Erivedge Royalties to Oberland Capital for up to $135.7 million

    LEXINGTON, Mass., March 25, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an agreement with funds managed by Oberland Capital Management, LLC ("Oberland Capital") for up to $135.7 million in exchange for selling rights to a portion of royalty revenues on worldwide net sales of Erivedge. Under the terms of the agreement, Curis received $65.0 million in an upfront cash payment, plus Curis is entitled to receive up to an additional $70.7 million in milestone payments if future net royalties exceed pre-defined annual and cumulative thresholds.

  • PR Newswire

    Curis to Release Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 26, 2019

    LEXINGTON, Mass., March 25, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter and full-year 2018 financial results on Tuesday, March 26, 2019, after the close of the US markets. Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology.

  • PR Newswire

    Curis Announces Presentation at Cowen & Company 39th Annual Healthcare Conference

    LEXINGTON, Mass. , March 4, 2019 /PRNewswire/ --   Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced ...

  • PR Newswire

    Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference

    LEXINGTON, Mass. , Feb. 4, 2019 /PRNewswire/ --   Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced ...

  • Has Curis (CRIS) Outpaced Other Medical Stocks This Year?
    Zacks

    Has Curis (CRIS) Outpaced Other Medical Stocks This Year?

    Is (CRIS) Outperforming Other Medical Stocks This Year?

  • PR Newswire

    First Mesothelioma Patient Dosed in CA-170 Study

    LEXINGTON, Mass., Jan. 24, 2019 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the first mesothelioma patient has been enrolled and dosed in the Phase I study of CA-170. CA-170 is an orally available, dual inhibitor of VISTA and PDL1, which the company believes could provide benefit in tumors with high levels of VISTA expression. The company had previously announced its expectation to begin enrollment of mesothelioma patients in a dedicated cohort within the existing Phase 1 study.